Jakob Dupont, EVP, Head of R&D at Atara Biotherapeutics, Inc. (ATRA), sold 2,221 shares at $9.86 ($22K) on 2022-03-01, disclosed to the SEC on 2022-03-03.
Scheduled sale ($22k) by EVP, Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ATRA | SELL | 2022-11-18 | $19K | — | Filing → |
| ATRA | SELL | 2022-08-18 | $21K | — | Filing → |
| ATRA | SELL | 2022-05-19 | $21K | — | Filing → |